Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.8%. By the end of trading, Alnylam Pharmaceuticals fell $0.71 (-1.1%) to $65.73 on average volume. Throughout the day, 669,569 shares of Alnylam Pharmaceuticals exchanged hands as compared to its average daily volume of 779,400 shares. The stock ranged in price between $64.74-$67.97 after having opened the day at $67.15 as compared to the previous trading day's close of $66.44. Other companies within the Drugs industry that declined today were:
), down 41.3%,
), down 24.8%,
), down 6.5% and
), down 6.2%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Alnylam Pharmaceuticals has a market cap of $3.9 billion and is part of the health care sector. Shares are up 264.1% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Alnylam Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.
- You can view the full Alnylam Pharmaceuticals Ratings Report.
On the positive front,
), up 33.7%,
), up 30.4%,
), up 17.5% and
), up 16.3% , were all gainers within the drugs industry with
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.